Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Mining the 'Sweat of the Sun' in Nevada

As the gold mining majors increasingly focus on Nevada deposits, they have taken notice of a small-cap explorer with prime properties. For billions of years, exploding neutron stars have been mass-producing cascades of the proton-heavy atom that we human...
Streetwise Reports | June 21, 2019 |

Biotech's New Mesothelioma Trial Data Show Efficacy, Immunogenicity

These results of a study evaluating Targovax's lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report. In a June 22 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Targovax ASA's (TRVX:OSE) ONCOS-102, in trial ...
Streetwise Reports | June 25, 2020 |

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia

Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/...
Streetwise Reports | November 5, 2019 |

ChemoCentryx Shares Spike 300% on Phase 3 ANCA Vasculitis Trial Results

Shares of ChemoCentryx Inc. opened greater than 330% higher today after the firm reported positive topline data from its pivotal Phase 3 ADVOCATE trial of Avacopan in treatment of ANCA-associated vasculitis. After the U.S. markets closed yesterday, ChemoCentryx Inc. ...
Streetwise Reports | November 27, 2019 |

After Biotech Dives Deeper Into Melanoma Data, It 'Continues to Impress'

Details from this clinical program are discussed, along with Q2/19 earnings and the next stock catalyst, in an H.C. Wainwright & Co. report. In an Aug. 23 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported the highlights from Targovax ASA's (TRVX:...
Streetwise Reports | August 28, 2019 |

Standard Lithium Arranges C$5 Million Convertible Loan Financing

The Critical Investor delves into a lithium company's financing and its implications. It seems more and more likely that Standard Lithium Ltd. (SLL:TSX.V; STLHF:OTCQX; FRA: S5L) is displaying a serious commitment of giant JV partner Lanxess these days, with constr...
Streetwise Reports | November 6, 2019 |

Zero-Commission Trading: Risks and Opportunities, Part 1

Part 1: What It All Means for Investors: Online brokers as investments. There's a financial war going on, and the fallout is causing tremors well beyond Wall Street. Investors armed with the right information can make the new zero-commissions standard work to their ad...
Streetwise Reports | November 21, 2019 |

Standard Lithium Demo Plant Operating Soon, First Production in 2022

This month, Standard Lithium Ltd. (SLL:TSX.V; STLHF:OTCQX) is targeted to switch on a relatively large-scale, proof-of-concept lithium extraction Demonstration Plant in southern Arkansas. If all goes reasonably as planned, it should take just a few months to prove the...
Streetwise Reports | January 24, 2020 |

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...
Streetwise Reports | September 24, 2019 |

Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'

The latest clinical trial results are dissected in a ROTH Capital Partners report. In a Sept. 26 research note, ROTH Capital Partners analyst Jerry Isaacson reported that AzurRx BioPharma Inc.'s (AZRX:NASDAQ) Phase 2 OPTION trial for lead candidate MS1819 in cystic ...
Streetwise Reports | October 1, 2019 |
1 2 3 4 5 6 7 8 9 10 ...